People on weekly injections saw heart-disease risk drop by 18%
Drugmaker’s shares gain, reaching highest level on record
Patients who took the diet drug Wegovy for a year had a reduced risk of heart disease, a promising finding that sent Novo Nordisk A/S shares to a record.
The stock rose as much as 3.1% in Copenhagen in response to study results presented over the weekend. Wegovy’s prodigious success has turned Novo into Europe’s second-most valuable firm behind the luxury group LVMH.
https://www.bloomberg.com/news/articles/2023-05-22/novo-gains-after-doctors-find-heart-risk-drops-on-wegovy
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.